+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Herpes Labialis - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • October 2021
  • Region: Global
  • DelveInsight
  • ID: 4340506
This “Herpes labialis - Pipeline Insight, 2021” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Herpes labialis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered


  • Global coverage

Herpes labialis Understanding


Herpes labialis: Overview


Herpes labialis, also known as HSV-1, or oral herpes, is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Symptoms of herpes include painful blisters or ulcers at the site of infection. The prevalence of oral herpes infection is 67% of adults worldwide. Herpes labialis or oral herpes is an infection of the mouth area that causes small, painful blisters to develop on the lips, gums or throat. These blisters are caused by the herpes simplex virus. Cold sores (herpes labialis) usually go away within 1-2 weeks, but they can be treated with antiviral medications, like acyclovir or topical antiviral creams such as docosanol (Abreva), to reduce pain and shorten healing time.

"Herpes labialis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes labialis pipeline landscape is provided which includes the disease overview and Herpes labialis treatment guidelines. The assessment part of the report embraces, in depth Herpes labialis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes labialis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights


The companies and academics are working to assess challenges and seek opportunities that could influence Herpes labialis R&D. The therapies under development are focused on novel approaches to treat/improve Herpes labialis.

Herpes labialis Emerging Drugs Chapters


This segment of the Herpes labialis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Herpes labialis Emerging Drugs


HDIT-101: Heidelberg ImmunoTherapeutics


HDIT-101 is a humanized monoclonal antibody, being developed by Heidelberg ImmunoTherapeutics as a topical application. The drug is in Phase II clinical studies for the treatment of Herpes labialis.

Herpes labialis: Therapeutic Assessment


This segment of the report provides insights about the different Herpes labialis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Herpes labialis


There are approx. 6+ key companies which are developing the therapies for Herpes labialis. The companies which have their Herpes labialis drug candidates in the most advanced stage, i.e. Phase II include, Heidelberg ImmunoTherapeutics.

Phases


This report covers around 6+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Herpes labialis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as


  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as


  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Herpes labialis: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Herpes labialis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes labialis drugs.

Herpes labialis Report Insights


  • Herpes labialis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Herpes labialis Report Assessment


  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Herpes labialis drugs?
  • How many Herpes labialis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes labialis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Herpes labialis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Herpes labialis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players


  • AiCuris
  • Heidelberg ImmunoTherapeutics
  • Ecogene 21
  • Beech Tree Labs
  • NanoViricides
  • Maxwell Biosciences

Key Products


  • BOR15001L7
  • HDIT-101
  • Pritelivir
  • BTL-TML

Research programme: Herpes simplex virus nanoparticle therapies

  • MXB-009

Table of Contents

Introduction

Executive Summary

Herpes labialis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Herpes labialis - Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis

HDIT-101: Heidelberg ImmunoTherapeutics
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I/II)
  • Comparative Analysis

Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities

Preclinical/Discovery Stage Products
  • Comparative Analysis

MXB-009: Maxwell Biosciences
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Herpes labialis Key Companies

Herpes labialis Key Products

Herpes labialis- Unmet Needs

Herpes labialis- Market Drivers and Barriers

Herpes labialis- Future Perspectives and Conclusion

Herpes labialis Analyst Views

AppendixList of Tables
Table 1 Total Products for Herpes labialis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Herpes labialis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AiCuris
  • Heidelberg ImmunoTherapeutics
  • Ecogene 21
  • Beech Tree Labs
  • NanoViricides
  • Maxwell Biosciences